TrialBritish journal of cancer2026

OPTIM: a randomized phase II trial of nivolumab followed by nivolumab-ipilimumab or docetaxel at progression in recurrent/metastatic squamous cell carcinoma of the head and neck (OPTIM; AIO-KHT-0117).

Viktor Grünwald et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.